Skip to content
Helping patients reclaim a life of possibility
Clear
Search
Menu
About us
Contact us
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
European Myeloma Day
News
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
MPE Masterclass 2025
Agenda
Travel, expenses and reimbursement process and criteria
Venue and location information
Health and safety policy
MPE Masterclass 2024
Venue and location information
Agenda
Travel, expenses and reimbursement process and criteria
Health and safety policy
MPE Masterclass 2023
Agenda
Travel, expenses and reimbursement process and criteria
Venue and location information
MPE Masterclass 2022
10th Anniversary and Masterclass 2021
AGM 2020
AGM 2020 Agenda
AGM 2020 Online Registration
AGM 2020 Location and logistic information
AGM 2020 Elections
AGM 2019
AGM 2019 Agenda
AGM 2019 Online Registration
AGM 2019 Location and logistic information
AGM 2019 Election
AGM 2018
AGM 2018 Agenda
AGM 2018 Activities
AGM 2018 Location
AGM 2017
AGM 2017 Agenda
AGM 2017 Location
AGM 2016
AGM 2016 Agenda
AGM 2016 Location
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
European Young Myeloma Patients Group
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Objectives and scope
Data available
Partners and collaborators
Research
Patient Evidence
Videos and webinars on patient evidence
Q&As on patient evidence
Horizon Europe
ASCERTAIN
CERTAINTY
IMI
Harmony
Sisaqol
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Subscribe to
our newsletter!
Subscribe here
AGM 2019 Online Registration
The deadline to submit applications ended on
February 2019
Go to Top
About MPE
Our members
Our board and staff
Medical Advisory Committee
Our Strategic Goals
Our funding
Get involved in MPE activities
Become a member
Contact us
Myeloma and AL Amyloidosis
About Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
Myeloma Awareness Month 2025
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
European Young Myeloma Patients Group
Research
Patient Evidence
Horizon Europe
IMI
Access and Policy
Myeloma Access Atlas
CEE workgroup on Access
Myeloma and AL amyloidosis Clinical Trial Navigator
EU HTA regulation
Educational Resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Patient guides
News
European Myeloma Day
Clear
Search
PopUp
I am a
*
Patient
Patient advocate
Caregiver
Doctor
Name
This field is for validation purposes and should be left unchanged.
